VistaGen Therapeutics reported a narrower-than-expected first-quarter loss and revenue that beat estimates. The company posted a GAAP loss of $0.30 per share, beating expectations by $0.06, while revenue of $1.48 million, up 516.7% year-over-year, beat by $1.31 million. Cash, cash equivalents, and marketable securities totaled $31.7 million as of June 30, 2026. VistaGen said its cash runway is expected to fund operations into 2027 but not for more than a year from now.
VistaGen Therapeutics IncNarrower loss and revenue beat estimates, with cash runway into 2027.